For the quarter ending 2025-09-30, TOVX has $30,836K in assets. $24,098K in debts. $7,528K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 7,528 | 12,120 | ||
| Tax credit receivable | 1,721 | 1,722 | ||
| Prepaid expenses and other current assets | 654 | 901 | ||
| Total current assets | 9,903 | 14,743 | ||
| Property and equipment, net | 249 | 258 | ||
| Restricted cash | 46 | 46 | ||
| Right of use asset | 942 | 1,077 | ||
| In-process research and development | 19,614 | 19,624 | ||
| Deposits and other assets | 82 | 82 | ||
| Total assets | 30,836 | 35,830 | ||
| Accounts payable | 795 | 607 | ||
| Accrued expenses | 7,685 | 9,017 | ||
| Accrued employee benefits | 747 | 759 | ||
| Deferred research and development tax credit-current portion | 1,101 | 1,343 | ||
| Loans payable-current | 57 | 56 | ||
| Operating lease liability-current portion | 618 | 612 | ||
| Total current liabilities | 11,003 | 12,394 | ||
| Non-current contingent consideration | 10,793 | 10,160 | ||
| Loan payable - non-current | 1,654 | 1,639 | ||
| Non-current deferred research and development tax credit | 215 | 430 | ||
| Non-current operating lease liability | 433 | 584 | ||
| Preferred stock 10,000,000 authorized none issued or outstanding at june 30, 2025 and december 31, 2024 | - | 0 | ||
| Total liabilities | 24,098 | 25,207 | ||
| Common stock, 0.001 par value 350,000,000 shares authorized, 10,333,572 issued and 10,304,762 outstanding at september 30, 2025 and 2,811,259 issued and 2,782,449 outstanding at december 31, 2024 | 9 | 8 | ||
| Additional paid-in capital | 362,968 | 362,463 | ||
| Treasury stock at cost, 28,809 shares at september 30, 2025 and at december 31, 2024 | 288 | 288 | ||
| Accumulated other comprehensive income (loss) | 763 | 793 | ||
| Accumulated deficit | -356,714 | -352,353 | ||
| Total stockholders' equity | 6,738 | 10,623 | ||
| Total liabilities and stockholders' equity | 30,836 | 35,830 | ||
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)